City

Bethesda (1)

Birmingham (1)

Houston (1)

New York (1)

Orlando (1)

Philadelphia (1)

Washington (1)

Condition

Chronic Lymphocytic Lymphoma (3)

B-Cell Lymphoma (1)

Follicular Lymphoma (1)

Hodgkin's Disease (1)

Mantle Cell Lymphoma (1)

Marginal Zone Lymphoma (1)

Multiple Myeloma (1)

Relapsed Non-Hodgkin's Lymphoma (1)

Overall Status

Completed (1)

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

phase 1 (2)

phase 1/phase 2 (1)

Sponsor

Gilead Sciences (1)

Icahn School of Medicine at Mount Sinai (1)

National Cancer Institute (NCI) (1)

Collaborator

Intervention

magrolimab (1)

milatuzumab (1)

mssm/biir hdc vax-001 (host dendritic cells) (1)

obinutuzumab (1)

venetoclax (1)

Study Documents

Intervention Type

biological (2)

drug (1)

Funder Type

Industry (1)

NIH (1)

Other (1)

Study Type

Interventional (3)

Chronic Lymphocytic Lymphoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting

Follicular Lymphoma
+4 more

Obinutuzumab
+2 more

Bethesda, Maryland

National Institutes of Health Clinical Center

Jan 20, 2023

Chronic Lymphocytic Lymphoma Trial in United States (milatuzumab)

Completed

Chronic Lymphocytic Lymphoma

milatuzumab

Birmingham, Alabama
+4 more

Aug 12, 2021

Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma Trial in New York (MSSM/BIIR HDC Vax-001 (Host Dendritic

Unknown status

Relapsed Non-Hodgkin's Lymphoma
+3 more

MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)

New York, New York

Mount Sinai Medical Center

Oct 28, 2010